SCHEMBL197972

SCHEMBL197972

COC(=O)c1ccc(C)c(O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.71
CA2 P00918 5/20 0.71
CA12 O43570 4/20 0.71
CA7 P43166 4/20 0.71
CA9 Q16790 4/20 0.71
CA14 Q9ULX7 4/20 0.71
XDH P47989 2/20 0.71
KDM4E B2RXH2 3/20 0.59
LMNA P02545 3/20 0.59
GAA P10253 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
POLB P06746 1/20 0.59
NFKB1 P19838 1/20 0.59
GFER P55789 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
FUT7 Q11130 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MAPT P10636 4/20 0.58
ALDH1A1 P00352 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30809635 1.00 CA1 (0.71) CA1CA2CA12CA7CA9
SCHEMBL10420429 0.90 CA12 (0.59) CA1CA2CA12CA7CA9
SCHEMBL19111153 0.85 EGFR (0.65) CA1CA2CA12CA7CA9
SCHEMBL172476 0.84 CA1 (0.71) CA1CA2CA12CA7CA9
SCHEMBL35783 0.83 MAPT (0.63) CA1CA2CA12CA7CA9
SCHEMBL30029511 0.83 MAPT (0.63) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL38624 0.83 CA1 (1.00) CA1CA2CA12CA7CA9
SCHEMBL15099889 0.83 CA1 (0.77) CA1CA2CA12CA7CA9
Methyl Protocatechuate SCHEMBL29360855 0.83 CA1 (1.00) CA1CA2CA12CA7CA9
SCHEMBL27885626 0.82 CA12 (0.49) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4712958-A2 USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Vandria SA (CH) 2026-03-25 EP disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor NIPPON SHINYAKU CO., LTD. (JP) 2025-12-30 US disclosed
WO-2025201504-A1 KAT6 INHIBITORS BEIGENE (SUZHOU) CO., LTD. (CN) 2025-10-02 WO disclosed
US-20250304535-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-10-02 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-12415816-B2 Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-09-16 US disclosed
EP-4561976-A2 UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS Vandria SA (CH) 2025-06-04 EP disclosed
CN-119948002-A Urolithin derivatives and therapeutic use 范徳利亚股份公司 2025-05-06 CN disclosed
US-4997844-A Compounds for the treatment of allergic or inflammatory diseases or shock conditions ICI AMERICAS INC. (US) 1991-03-05 US disclosed
EP-0179619-B1 HETEROCYCLIC AMIDES ICI AMERICAS INC. (US) 1990-09-05 EP disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
US-4920140-A Skin disorders CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) 1990-04-24 US disclosed
US-4740519-A Benzo (b) thiophene carboxylate derivatives and pharmaceutical compositions CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) 1988-04-26 US disclosed
CN-85108623-A Preparation has the novel method of the heterocycleamide of medical active 1986-07-30 CN disclosed
EP-0179619-A1 Heterocyclic amides ICI AMERICAS INC. (US) 1986-04-30 EP disclosed
EP-0083228-B1 PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES ICI AMERICAS INC. (US) 1985-05-15 EP disclosed
US-4499299-A Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1985-02-12 US disclosed
EP-0083228-A1 Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1983-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415816-B2 Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof JAK2, JAK1, JAK3 CA1 3248/4885CA2 1691/4885CA12 3047/4885
US-20250304535-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT2A CA1 1153/4885CA2 3028/4885CA12 2995/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B CA1 3170/4885CA2 3912/4885CA12 4071/4885
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor PDGFRA, PDGFRB, PDGFA CA1 3118/4885CA2 339/4885CA12 3717/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B CA1 2723/4885CA2 3408/4885CA12 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.